Literature DB >> 7590652

The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age.

M H Chang1, H Y Hsu, H C Hsu, Y H Ni, J S Chen, D S Chen.   

Abstract

To investigate the significance of spontaneous hepatitis B e antigen (HBeAg) seroconversion during childhood, 415 hepatitis B surface antigen (HBsAg) carrier children (ages 0 to 15 years) were prospectively followed for 7.1 +/- 2.9 years. Hepatitis B virus (HBV) markers and liver function profiles of each child were tested at least once every 6 months. Among them, 50 were initially anti-HBe positive and 140 seroconverted from HBeAg to anti-HBe during follow-up. Before HBeAg seroconversion, jaundice occurred in 9 and alanine transaminase (ALT) activities elevated in 99 of the 140 seroconverters. Serum ALT returned to normal in all patients within 1 to 5 years of seroconversion. Six had reelevated ALT later after seroconversion. Only 7 (9.7%) of the 72 carrier infants seroconverted before 3 years of age. The peak ALT levels in five of them exceeded 100 IU/L, and two had jaundice before HBeAg seroconversion. One of the early seroconverters developed hepatocellular carcinoma (HCC) at 11 years of age, although his liver function profiles remained normal after HBeAg seroconversion. Liver biopsy specimens from 30 children during the anti-HBe-positive stag e showed inactive cirrhosis in 2 (including one with HCC), chronic hepatitis with marked fibrosis in 1, mild activity and moderate fibrosis in 2, mild activity and mild fibrosis in 9, and minimal histologic changes in the remaining 16. Although most will achieve a normalization of ALT and inactive liver histologic changes, the seroconversion of HBsAg carrier children from HBeAg to anti-HBe is not necessarily an indicator of favorable prognosis; a small proportion of children will develop cirrhosis or even HCC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7590652

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  28 in total

1.  Determinants for the occurrence of acute exacerbation of hepatitis B virus infection in Chinese patients after HBeAg seroclearance.

Authors:  He-Jun Yuan; Man-Fung Yuen; Danny Ka-Ho Wong; Siu-Man Sum; Joke Doutreloigne; Erwin Sablon; Ching-Lung Lai
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 2.  Chronic viral hepatitis.

Authors:  M H Chang
Journal:  Indian J Pediatr       Date:  1995 Nov-Dec       Impact factor: 1.967

3.  Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors:  Carla S Coffin; Scott K Fung; Mang M Ma
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

4.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 5.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

Review 6.  Natural history of hepatitis B virus infection: pediatric perspective.

Authors:  Yen-Hsuan Ni
Journal:  J Gastroenterol       Date:  2010-09-02       Impact factor: 7.527

7.  HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B.

Authors:  Yun-Fan Liaw
Journal:  Hepatol Int       Date:  2009-06-24       Impact factor: 6.047

8.  Natural history and clinical management of chronic hepatitis B virus infection in children.

Authors:  Mei-Hwei Chang
Journal:  Hepatol Int       Date:  2008-03-06       Impact factor: 6.047

9.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2012-06-26

10.  Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C.

Authors:  Yen-Tsung Huang; Chin-Lan Jen; Hwai-I Yang; Mei-Hsuan Lee; Jun Su; Sheng-Nan Lu; Uchenna H Iloeje; Chien-Jen Chen
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.